Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Clin Endocrinol Metab ; 103(4): 1583-1591, 2018 04 01.
Article in English | MEDLINE | ID: mdl-29346569

ABSTRACT

Context and Objective: The Controlled Antenatal Thyroid Screening (CATS) study investigated treatment of suboptimal gestational thyroid function (SGTF) on childhood cognition and found no difference in intelligence quotient (IQ) at 3 years between children of treated and untreated SGTF mothers. We have measured IQ in the same children at age 9.5 years and included children from normal gestational thyroid function (normal-GTF) mothers. Design, Setting, and Participants: One examiner, blinded to participant group, assessed children's IQ (Wechsler Intelligence Scale for Children, Fourth Edition UK), long-term memory, and motor function (Developmental Neuropsychological Assessment II) from children of 119 treated and 98 untreated SGTF mothers plus children of 232 mothers with normal-GTF. Logistic regression explored the odds and percentages of an IQ < 85 in the groups. Results: There was no difference in IQ < 85 between children of mothers with normal-GTF and combined SGTF, i.e., treated and untreated (fully adjusted odds ratio [OR] = 1.15 [95% confidence interval (CI) 0.52, 2.51]; P = 0.731). Furthermore, there was no significant effect of treatment [untreated OR = 1.33 (95% CI 0.53, 3.34); treated OR = 0.75 (95% CI 0.27, 2.06) P = 0.576]. IQ < 85 was 6.03% in normal-GTF, 7.56% in treated, and 11.22% in untreated groups. Analyses accounting for treated-SGTF women with free thyroxine > 97.5th percentile of the entire CATS-I cohort revealed no significant effect on a child's IQ < 85 in CATS-II. IQ at age 3 predicted IQ at age 9.5 (P < 0.0001) and accounted for 45% of the variation. Conclusions: Maternal thyroxine during pregnancy did not improve child cognition at age 9.5 years. Our findings confirmed CATS-I and suggest that the lack of treatment effect may be a result of the similar proportion of IQ < 85 in children of women with normal-GTF and SGTF.


Subject(s)
Cognition/drug effects , Hypothyroidism/drug therapy , Intelligence/drug effects , Pregnancy Complications/drug therapy , Prenatal Exposure Delayed Effects/psychology , Thyroxine/therapeutic use , Adult , Child , Female , Humans , Hypothyroidism/diagnosis , Intelligence Tests , Male , Pregnancy , Pregnancy Complications/diagnosis , Prenatal Diagnosis , Thyroid Function Tests , Thyroxine/administration & dosage
2.
BMC Endocr Disord ; 14: 95, 2014 Dec 12.
Article in English | MEDLINE | ID: mdl-25495390

ABSTRACT

BACKGROUND: Children whose mothers had low thyroid hormone levels during pregnancy have been reported to have decreased cognitive function. The reported research is part of the follow-on study of the Controlled Antenatal Thyroid Screening Study (CATS I), a randomised controlled trial which investigated the impact of treated vs. untreated low thyroid hormone level in women during pregnancy with the primary outcome being the child's IQ at age 3. No significant differences in IQ were found between the treated and untreated groups. These children are now aged between 7 and 10 years and aspects of their cognitive functioning including their IQ are being reassessed as part of CATS II. METHODS/DESIGN: Cognitive assessments generate an IQ score and further tests administered will investigate long term memory function and motor coordination. The aim is to complete the assessments with 40% of the children born to mothers either in the treated or untreated low thyroid hormone groups (n = 120 per group). Also children born to mothers who had normal thyroid functioning during CATS I are being assessed for the first time (n = 240) to provide a comparison. Assessments are conducted either in the research facility or the participant's home. DISCUSSION: The study is designed to assess the cognitive functioning of children born to mothers with low thyroid hormone levels and normal thyroid functioning during pregnancy. This is the largest study of its type and also is distinguishable in its longitudinal design. The research has the potential to have a significant impact on public health policy in the UK; universal screening of thyroid hormone levels in pregnancy may be the recommendation.


Subject(s)
Intelligence Tests , Intelligence , Iodine/deficiency , Motor Skills , Pregnancy Complications/metabolism , Prenatal Diagnosis , Thyroid Hormones/deficiency , Adult , Child , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Pregnancy , Prenatal Diagnosis/methods , Thyroid Function Tests , United Kingdom/epidemiology
3.
J Clin Endocrinol Metab ; 99(11): 4291-8, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25057878

ABSTRACT

OBJECTIVE: Thyroid dysfunction is associated with impaired cognitive development. Perchlorate decreases thyroidal iodine uptake, potentially reducing thyroid hormone production. It is unclear whether perchlorate exposure in early life affects neurodevelopment. DESIGN: Historical cohort analysis. PATIENTS: From 2002 to 2006, 21,846 women at gestational age <16 weeks recruited from antenatal clinics in Cardiff, UK and Turin, Italy were enrolled in the Controlled Antenatal Thyroid Screening Study (CATS). We undertook a retrospective analysis of 487 mother-child pairs in mothers who were hypothyroid/hypothyroxinemic during pregnancy and analyzed whether first trimester maternal perchlorate levels in the highest 10% of the study population were associated with increased odds of offspring IQ being in the lowest 10% at 3 years of age. MAIN OUTCOME MEASURES: Maternal urinary perchlorate, offspring IQ. RESULTS: Urine perchlorate was detectable in all women (median 2.58 µg/L); iodine levels were low (median 72 µg/L). Maternal perchlorate levels in the highest 10% of the population increased the odds of offspring IQ being in the lowest 10% OR = 3.14 (95% CI 1.38, 7.13) P = .006 with a greater negative impact observed on verbal OR = 3.14 (95% CI 1.42, 6.90) P = .005 than performance IQ. Maternal levothyroxine therapy did not reduce the negative impact of perchlorate on offspring IQ. CONCLUSIONS: This is the first study using individual-level patient data to study maternal perchlorate exposure and offspring neurodevelopment and suggests that high-end maternal perchlorate levels in hypothyroid/hypothyroxinemic pregnant women have an adverse effect on offspring cognitive development, not affected by maternal levothyroxine therapy. These results require replication in additional studies, including in the euthyroid population.


Subject(s)
Hypothyroidism/urine , Intelligence , Perchlorates/urine , Pregnancy Complications/urine , Prenatal Exposure Delayed Effects/psychology , Thyroid Gland/physiopathology , Child, Preschool , Cognition , Female , Humans , Hypothyroidism/physiopathology , Hypothyroidism/psychology , Maternal Exposure , Neuropsychological Tests , Pregnancy , Pregnancy Complications/physiopathology , Pregnancy Complications/psychology , Prenatal Exposure Delayed Effects/chemically induced , Retrospective Studies , Thyroid Function Tests
4.
N Engl J Med ; 366(6): 493-501, 2012 Feb 09.
Article in English | MEDLINE | ID: mdl-22316443

ABSTRACT

BACKGROUND: Children born to women with low thyroid hormone levels have been reported to have decreased cognitive function. METHODS: We conducted a randomized trial in which pregnant women at a gestation of 15 weeks 6 days or less provided blood samples for measurement of thyrotropin and free thyroxine (T(4)). Women were assigned to a screening group (in which measurements were obtained immediately) or a control group (in which serum was stored and measurements were obtained shortly after delivery). Thyrotropin levels above the 97.5th percentile, free T(4) levels below the 2.5th percentile, or both were considered a positive screening result. Women with positive findings in the screening group were assigned to 150 µg of levothyroxine per day. The primary outcome was IQ at 3 years of age in children of women with positive results, as measured by psychologists who were unaware of the group assignments. RESULTS: Of 21,846 women who provided blood samples (at a median gestational age of 12 weeks 3 days), 390 women in the screening group and 404 in the control group tested positive. The median gestational age at the start of levothyroxine treatment was 13 weeks 3 days; treatment was adjusted as needed to achieve a target thyrotropin level of 0.1 to 1.0 mIU per liter. Among the children of women with positive results, the mean IQ scores were 99.2 and 100.0 in the screening and control groups, respectively (difference, 0.8; 95% confidence interval [CI], -1.1 to 2.6; P=0.40 by intention-to-treat analysis); the proportions of children with an IQ of less than 85 were 12.1% in the screening group and 14.1% in the control group (difference, 2.1 percentage points; 95% CI, -2.6 to 6.7; P=0.39). An on-treatment analysis showed similar results. CONCLUSIONS: Antenatal screening (at a median gestational age of 12 weeks 3 days) and maternal treatment for hypothyroidism did not result in improved cognitive function in children at 3 years of age. (Funded by the Wellcome Trust UK and Compagnia di San Paulo, Turin; Current Controlled Trials number, ISRCTN46178175.).


Subject(s)
Hypothyroidism/diagnosis , Intelligence , Pregnancy Complications/diagnosis , Prenatal Diagnosis , Thyrotropin/blood , Thyroxine/therapeutic use , Child, Preschool , Female , Gestational Age , Humans , Hypothyroidism/drug therapy , Intellectual Disability/diagnosis , Intellectual Disability/etiology , Intelligence Tests , Intention to Treat Analysis , Male , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Trimester, Second/blood , Prenatal Exposure Delayed Effects/diagnosis , Thyroid Hormones/metabolism , Thyroxine/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...